EpilepsyGTx

1-1 with Gabriele Lignani on gene therapy innovations, EpilepsyGTx, and entrepreneurship. Gabriele Lignani, EpilepsyGTx co-founder and scientific advisor, joined AlbionVC partner Simon Goldman for another episode of our founder stories. The biotech startup recently raised $10m in a seed funding round led by us via the UCL Technology Fund. Aside from his role at Epilepsy GTX, Gabriele is also a professor of Translational Neuroscience at UCL and, in this chat, he shares how his journey started with UCL's renowned epilepsy research programme in 2014. Through the relationship with Simon and the collaboration at UCL, Gabriele realised the need to prioritise the translational pathway and early patenting, integrating clinical applications with theoretical research to align research with patient needs.    He advises combining basic and translational research, engaging with commercialisation experts, and collaborating across disciplines.   Watch the full interview here: https://lnkd.in/ej6XjCvY    Founder Stories University Edition is a captivating series of fireside chats featuring academic founders backed by AlbionVC, which has invested in over 30 UK university spinouts.    UCL Technology Fund UCL Business Ltd #lifesciences #genetherape #research #epilepsy #biotech #UCL #lab #tech #founders #cofounder #startups #entrepreneurs #venturecapital #founderstories

HTH has just made a new investment: EpilepsyGTx! EpilepsyGTx is pioneering innovative gene therapies for focal refractory epilepsy with the mission to make patients seizure-free. We are confident that EpilepsyGTx's groundbreaking solutions will make a significant impact, and we are proud to support this outstanding team.

Huge congratulations to EpilepsyGTx, a late preclinical-stage biotech developing cutting-edge gene therapies to treat focal refractory epilepsy (FRE), on its recent milestone $10m seed raise to advance their lead gene therapy program EPY201. The financing was led by us via the UCL Technology Fund, with participation from HTH Simon Goldman Partner AlbionVC who has worked with the team since the start said: “EpilepsyGTx has an objectively world-leading pipeline of genetic therapies for a common and damaging neurological disorder with few treatment options, developed by a globally-renowned clinical, scientific and translational team at the UCL Queen Square Institute of Neurology. We are enormously pleased to have Nicolas Koebel on board as CEO, with a track record of building exceptional global biotech companies from inception to commercial launch. We are excited that this industry-leading team now has the opportunity to translate medicines that have the potential to change the lives of patients with epilepsy and other CNS disorders.” Read more here: https://lnkd.in/e9yaXzJ7 UCL Technology Fund, UCL Business Ltd #lifesciences #epilepsy #biotech #UCLspinout #lab #tech #uktech #founders #cofounder #startups #entrepreneurs #venturecapital

Today we emerge from stealth mode and officially launch EpilepsyGTx!